Home
About Us
Information & Guidelines
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
Information For Authors
Information Editorial Board
Contact Us
FAQ
Paper Submission Guideline
Register
Login
Submit Now
Vol - 28, Issue - 04
Full-Text PDF
About the Journal
Download
[This article belongs to Volume - 28, Issue - 04]
International Medical Journal
Journal ID
:
IMJ-07-08-2021-834
Total View
:
675
Title
:
Mechanism Based evidences to prove ACE Inhibitors and ARB may prove beneficial in light of COVID 19
Abstract
: <p>ACE2 is a type one transmembrane metallo carboxypeptidase with similarity to ACE. Heart, vessels, gut, kidney, respiratory organ, testicle, brain these are the organ in which ACE2 receptor is widely expressed. It acts as a key player in renin angiotensin system and serves as a target for the treatment of cardiovascular diseases. Angiotensin II, a compound with angiotensin converting enzyme (ACE) activity, regulates vascular tone, stimulates the development of proinflammatory cytokines, inhibits NFkappaB, enhances oxidant stress, and suppresses nitric oxide synthesis. Thus, angiotensin-II is basically pro-inflammatory, thus the ACE inhibitors and ARBs used as therapeutic agents will reverse this effect and will decrease inflammatory mediators. ACE inhibitors and the ARBs will decrease the renal damage of SARS COV nephropathy by reducing the macrophage infiltration. Current evidence does not prove any negative impact of ARB and ACEI on Covid-19. It is clear from the mechanism based evidences that the ACE inhibitors and the ARBs are having much more benefits and show evidence of efficacy and show promise in tackling all the three dangerous comorbidities of SARS COV 2 i.e. Heart disease, glomerular diseases and Diabetes Mellitus, discontinuing them only for the sake of small increase in ACE II expression will be unjustified. Those patients having the indications can be continued for ACE inhibitors and the ARBs with or without SARS COV 2.</p>
Download Info
×
Paper Access Key
Access Key
Submit
No Access Key (
Request for Download
)
Name
Email
Country
Send Request
Our Certificates
Guidelines
Information For Authors
Information Editorial Board
FAQ
Further Information
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
//